Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Radiotherapy, Irinotecan Liposome, Apatinib, and Camrelizumab in Advanced Solid Tumors
NCT04569916Phase 2Unknown
- Sponsor
- Nanjing Drum-Tower Hospital
- Start
- Sep 2020
- Primary completion
- Feb 2023
- Modality
- Immune Checkpoint Inhibitors, Lipid-based Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of camrelizumab, Rivoceranib and irinotecan liposome in solid tumor, sponsored by Nanjing Drum-Tower Hospital. Primary endpoint: Objective Response Rate at 2 years. Status: unknown.
02
Drugs
camrelizumabRivoceranibirinotecan liposome
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT04569916.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04569916.